Avatar Therapeutics

Avatar Therapeutics is a gene therapy research and development company dedicated to developing the next generation of AAV (adeno-associated virus). The company develops in vivo gene therapy products based on artificial intelligence (AI) deep learning algorithms, with therapies delivered intravenously using AAV9 capable of crossing the blood-brain barrier (BBB). Meanwhile, Avatar Therapeutics focuses on designing AAV capsids to overcome immune responses during administration. It is reported that this round of financing will be used for automating the vector engineering, production processes, and vector design that constitute the AAV gene therapy platform.